See feature articles below:
About Broad Street Alerts:
Big opportunities in Small Cap’s
Broad Street Alerts recent profiles and track record, 217% in verifiable potential gains for our members on the last 4 small cap alerts alone!
February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%
March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.
March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.
April 11th, 2016 – (NASDAQ: FNJN) called at $1.07/share hit $1.76/share in 3 days for 64% gains for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.
We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
–Report on:(Nasdaq:ONTY ACAD )
Oncothyreon Inc (ONTY) ended last trading session with a change of -2.96 percent. It trades at an average volume of 883.79K shares versus 1.73M shares recorded at the end of last trading session. The share price of $1.31 is at a distance of 45.56 percent from its 52-week low and down -72.07 percent versus its peak. The company has a market cap of $121.36M and currently has 92.64M shares outstanding. The share price is currently 8.94 percent versus its SMA20, 14.85 percent versus its SMA50, and -45.34 percent versus its SMA200. The stock has a weekly performance of 7.38 percent and is -40.99 percent year-to-date as of the recent close.
Oncothyreon Inc (ONTY) on April 19, 2016 announced the presentation of data highlighting the preclinical development of orally bioavailable, potent and selective checkpoint kinase 1 (Chk1) inhibitors. Results were presented at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans.
Chk1 is a protein kinase that plays a major role in the ability of cancer cells to respond to DNA damage and DNA replication stress. As a single agent, Chk1 inhibitors may selectively target cancer cells that have high replication stress, which can be caused by activation of oncogenic signaling and loss of tumor suppressor functions. Chk1 inhibitors may also be used in combination with chemotherapy, potentially enhancing cell death and increasing the efficacy of these agents.
ACADIA Pharmaceuticals Inc. (ACAD) recently recorded -4.56 percent change and currently at $32.62 is 96.03 percent away from its 52-week low and down -37.26 percent versus its peak. It has a past 5-day performance of -3.09 percent and trades at an average volume of 3.12M shares. The stock has a 1-month performance of 60.61 percent and is -8.5 percent year-to-date as of the recent close. There were about 111.54M shares outstanding which made its market cap $3.64B. The share price is currently 3.63 percent versus its SMA20, 33.42 percent versus its SMA50, and -0.7 percent versus its SMA200.
ACADIA Pharmaceuticals Inc. (ACAD) on March 29, 2016 announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted 12 to 2 that the benefits of NUPLAZID™ (pimavanserin) for the treatment of psychosis associated with Parkinson’s disease outweigh the risks of treatment.
The Prescription Drug User Fee Act (PDUFA) action date for completion of FDA review of the NUPLAZID New Drug Application (NDA) is May 1, 2016. The FDA has granted the NUPLAZID NDA Priority Review status and designated NUPLAZID for the treatment of psychosis associated with Parkinson’s disease as a Breakthrough Therapy.
The Advisory Committee provides the FDA with independent expert advice and recommendations on the safety and efficacy of potential new medicines. The FDA is not bound by the Committee’s recommendation, but takes its advice into consideration when reviewing new drug applications.
Broad street alerts has not been compensated for the mention of any publicly traded companies in this article nor do we own positions in any of the companies in this article.
Broad Street Alerts was previously compensated eighteen thousand five hundred dollars by star media llc for the mention of FNJN however, that contract has expired.